Compare Amgen, Inc. (AMGN) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5. The key difference: Amgen, Inc. pays a 2.77% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | BIL | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Fixed Income |
52-Week High | $388.16 | $91.77 |
52-Week Low | $271.18 | $91.27 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BIL (SPDR Bloomberg 1-3 Month T-Bill ETF) trades at $91.50 with minimal daily movement, reflecting its stable Treasury bill portfolio. The ETF maintains consistent $0.27 quarterly dividends and shows bearish technical signals despite neutral oscillators. Recent market focus compares short-term Treasury ETFs like BIL against money market alternatives as investors seek yield amid Federal Reserve policy uncertainty.
BIL offers low-risk cash parking with Treasury bill exposure, but faces pressure from potential Fed rate hikes that could impact short-term yields. The ETF's stability appeals to risk-averse investors, though higher-yielding alternatives may emerge if rates rise further. Current technical weakness suggests cautious near-term positioning despite fundamental safety.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
